ArticleJournal of experimental & clinical cancer research : CR2021

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.

Lijia Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.